Monopar Appoints Octávio Costa, MD, as Chief Medical
Officer
WILMETTE,
Ill., July 12, 2021 – Monopar
Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company primarily focused on developing
proprietary therapeutics designed to extend life or improve the
quality of life for cancer patients, today announced the
appointment of Octávio Costa,
MD, as Chief Medical Officer. In this role, Dr. Costa will oversee
global clinical development and regulatory affairs, and will
provide strategic direction for Monopar’s
pipeline.
Dr. Costa joins
Monopar with over 30 years of experience overseeing clinical
development, clinical operations, development strategy and global
medical affairs. He has extensive Phase 1 through 4 clinical
development expertise as well as regulatory experience. Dr.
Costa’s previous roles include positions of increasing
responsibility in clinical development at Merck, Celgene, Novartis
and most recently as Chief Medical Officer at Rafael
Pharmaceuticals. He has played an important role in the development
and life-cycle management of significant products, including the
blockbuster product REVLIMID® (lenalidomide).
Dr. Costa earned his Doctor of Medicine from The Medical College of
Sorocaba, São Paulo.
“We are excited
to welcome Octávio, especially as our lead
program enters late-stage clinical studies,” said Chandler
Robinson, MD, Chief Executive Officer of Monopar.
“Octávio’s track record of navigating all stages
of clinical development will aid Monopar in executing our growing
clinical development pipeline.”
“I am thrilled to be joining this accomplished management
team, as Monopar’s Chief Medical Officer,” said Dr.
Costa. “My industry knowledge and expertise in moving cancer
therapies through all stages of clinical testing is well suited to
help accelerate Monopar’s pipeline of innovative mid- and
late-stage clinical programs and early drug development
candidates.”
About Monopar Therapeutics Inc.
Monopar Therapeutics is a
clinical-stage biopharmaceutical company primarily focused on
developing proprietary therapeutics designed to extend life or
improve the quality of life for cancer
patients. Monopar's pipeline consists
of Validive for the prevention of
chemoradiotherapy-induced severe oral mucositis in oropharyngeal
cancer patients; camsirubicin for the treatment of
advanced soft tissue sarcoma; a late-stage preclinical antibody,
MNPR-101, for advanced cancers and severe COVID-19; and an
early-stage camsirubicin analog, MNPR-202, for various
cancers. For more information,
visit: www.monopartx.com.
Forward-Looking
Statements
Statements contained in this press
release regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. The words
“may,” “will,” “could,”
“would,” “should,” “expect,”
“plan,” “anticipate,” “intend,”
“believe,” “estimate,”
“predict,” “project,”
“potential,” “continue,”
“target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying
words. Examples of these forward-looking statements
include statements concerning Dr. Costa providing strategic
direction for Monopar’s pipeline and Dr. Costa aiding in
executing or accelerating Monopar clinical
development. The
forward-looking statements involve risks and uncertainties
including, but not limited to Dr. Costa’s unknown future
contributions to Monopar and
the significant general risks and uncertainties surrounding the
research, development, regulatory approval, and commercialization
of therapeutics. Actual results may differ materially from those expressed
or implied by such forward-looking statements. Risks are described
more fully in Monopar's filings with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were
made. Monopar undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made. Any forward-looking
statements contained in this press release represent
Monopar’s views only as of the date hereof and should
not be relied upon as representing its views as of any subsequent
date.
CONTACT:
Monopar Therapeutics
Inc.
Investor Relations
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx
LinkedIn:
Monopar Therapeutics